1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Medicine
  4. Volume 73, 2022
  5. Article

Annual Review of Medicine

Volume 73, 2022

COVID-19 and Diabetes

Abstract

The prevalence of diabetes in people with coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has varied worldwide. Most of the available evidence suggests a significant increase in severity and mortality of COVID-19 in people with either type 1 (T1DM) or type 2 diabetes mellitus (T2DM), especially in association with poor glycemic control. While new-onset hyperglycemia and new-onset diabetes (both T1DM and T2DM) have been increasingly recognized in the context of COVID-19 and have been associated with worse outcome, no conclusive evidence yet suggests direct tropism of SARS-CoV-2 on the β cells of pancreatic islets. While all approved oral antidiabetic agents appear to be safe in people with T2DM having COVID-19, no conclusive data are yet available to indicate a mortality benefit with any class of these drugs, in the absence of large randomized controlled trials.

Keyword(s): antidiabetic drugs, COVID-19, mortality, SARS-CoV-2, severity, type 1 diabetes, type 2 diabetes
Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-042220-011857
2022-01-27
2025-04-19
Loading full text...

Full text loading...

/deliver/fulltext/med/73/1/annurev-med-042220-011857.html?itemId=/content/journals/10.1146/annurev-med-042220-011857&mimeType=html&fmt=ahah

Literature Cited

  1. 1. 
    World Health Organization. 2021.. WHO Coronavirus (COVID-19) Dashboard. Accessed Apr. 16, 2021. https://covid19.who.int/
    [Google Scholar]
  2. 2. 
    Yang JK, Feng Y, Yuan MY, et al. 2006.. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. . Diabet. Med. 23:(6):623–28
     [Google Scholar]
  3. 3. 
    Allard R, Leclerc P, Tremblay C, Tannenbaum TN. 2010.. Diabetes and the severity of pandemic influenza A (H1N1) infection. . Diabetes Care 33:(7):1491–93
     [Google Scholar]
  4. 4. 
    Alraddadi BM, Watson JT, Almarashi A, et al. 2016.. Risk factors for primary Middle East respiratory syndrome coronavirus illness in humans. . Emerg. Infect. Dis. 22::49–55
     [Google Scholar]
  5. 5. 
    Cariou B, Hadjadj S, Wargny M, et al. 2020.. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. . Diabetologia 63::1500–15
     [Google Scholar]
  6. 6. 
    Shi Q, Zhang X, Jiang F, et al. 2020.. Clinical characteristics and risk factors for mortality of COVID-19 patients with diabetes in Wuhan, China: a two-center, retrospective study. . Diabetes Care 43::1382–91
     [Google Scholar]
  7. 7. 
    Seiglie J, Platt J, Cromer SJ, et al. 2020.. Diabetes as a risk factor for poor early outcomes in patients hospitalized with COVID-19. . Diabetes Care 43:(12):2938–44
     [Google Scholar]
  8. 8. 
    Agarwal S, Schechter C, Southern W, et al. 2020.. Preadmission diabetes-specific risk factors for mortality in hospitalized patients with diabetes and coronavirus disease 2019. . Diabetes Care 43::2339–44
     [Google Scholar]
  9. 9. 
    Singh AK, Gilles C, Singh R, et al. 2020.. Prevalence of comorbidities and their association with mortality in patients with COVID-19: a systematic review and meta-analysis. . Diabetes Obes. Metab. 22::1915–24
     [Google Scholar]
  10. 10. 
    Williamson EJ, Walker AJ, Bhaskaran K, et al. 2020.. Factors associated with COVID-19-related death using OpenSAFELY. . Nature 584:(7821):430–36
     [Google Scholar]
  11. 11. 
    Dennis JM, Mateen BA, Sonabend R, et al. 2020.. Type 2 diabetes and COVID-19-related mortality in the critical care setting: a national cohort study in England. . Diabetes Care 44:(1):50–57
     [Google Scholar]
  12. 12. 
    Clift AK, Coupland CAC, Keogh RH, et al. 2020.. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. . BMJ 371::m3731
     [Google Scholar]
  13. 13. 
    Holman N, Knighton P, Kar P, et al. 2020.. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. . Lancet Diabetes Endocrinol. 8::823–33
     [Google Scholar]
  14. 14. 
    Barron E, Bakhai C, Kar P, et al. 2020.. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. . Lancet Diabetes Endocrinol. 8::813–22
     [Google Scholar]
  15. 15. 
    Singh AK, Singh R. 2020.. At-admission hyperglycemia is consistently associated with poor prognosis and early intervention can improve outcomes in patients with COVID-19. . Diabetes Metab. Syndr. 14::1641–44
     [Google Scholar]
  16. 16. 
    Singh AK, Singh R. 2020.. Hyperglycemia without diabetes and new-onset diabetes are both associated with poorer outcomes in COVID-19. . Diabetes Res. Clin. Pract. 167::108382
     [Google Scholar]
  17. 17. 
    Potier L, Julla JB, Roussel R, et al. 2020.. COVID-19 symptoms masking inaugural ketoacidosis of type 1 diabetes. . Diabetes Metab. 47:(1):101162
     [Google Scholar]
  18. 18. 
    Kamrath C, Monkemoller K, Biester T, et al. 2020.. Ketoacidosis in children and adolescents with newly diagnosed type 1 diabetes during the COVID-19 pandemic in Germany. . JAMA 324::801–4
     [Google Scholar]
  19. 19. 
    Tittel SR, Rosenbauer J, Kamrath C, et al. 2020.. Did the COVID-19 lockdown affect the incidence of pediatric type 1 diabetes in Germany?. Diabetes Care 43::e172–73
     [Google Scholar]
  20. 20. 
    Unsworth R, Wallace S, Oliver NS, et al. 2020.. New-onset type 1 diabetes in children during COVID-19: multicenter regional findings in the U.K. . Diabetes Care 43::e170–71
     [Google Scholar]
  21. 21. 
    Ceriello A, Nigris VD, Prattichizzo F. 2020.. Why is hyperglycaemia worsening COVID-19 and its prognosis?. Diabetes Obes. Metab. 22::1951–52
     [Google Scholar]
  22. 22. 
    Apicella M, Campopiano MC, Mantuano M, et al. 2020.. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. . Lancet Diabetes Endocrinol. 8:(9):782–92
     [Google Scholar]
  23. 23. 
    Singh AK, Singh R, Saboo B, Misra A. 2020.. Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: a critical appraisal of literature. . Diabetes Metab. Syndr. 15:(1):159–67
     [Google Scholar]
  24. 24. 
    Huang C, Wang Y, Li X, et al. 2020.. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. . Lancet 395:(10223):497–506
     [Google Scholar]
  25. 25. 
    Singh AK, Gupta R, Ghosh A, Misra A. 2020.. Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations. . Diabetes Metab. Syndr. 14:(4):303–10
     [Google Scholar]
  26. 26. 
    Epidemiol. Work. Group NCIP Epidemic Response. 2020.. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. . Chin. J. Epidemiol. 41:(2):145–51
     [Google Scholar]
  27. 27. 
    CDC COVID-19 Response Team. 2020.. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019—United States, February 12–March 28, 2020. . Morb. Mortal. Wkly. Rep. 13::382–86
     [Google Scholar]
  28. 28. 
    Grasselli G, Zangrillo A, Zanella A, et al. 2020.. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. . JAMA 323:(16):1574–81
     [Google Scholar]
  29. 29. 
    Docherty AB, Harrison EM, Green CA, et al. 2020.. Features of 20133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. . BMJ 369::m1985
     [Google Scholar]
  30. 30. 
    Prieto-Alhambra D, Ballo E, Coma E, et al. 2020.. Hospitalization and 30-day fatality in 121,263 COVID-19 outpatient cases. . medRxiv https://doi.org/10.1101/2020.05.04.20090050
    [Crossref]
  31. 31. 
    Bello-Chavolla OY, Bahena-Lopez JP, Antonio-Villa NE, et al. 2020.. Predicting mortality due to SARS-CoV-2: a mechanistic score relating obesity and diabetes to COVID-19 outcomes in Mexico. . J. Clin. Endocrinol. Metab. 105:(8):dgaa346
     [Google Scholar]
  32. 32. 
    Almazeedi S, Al-Youha S, Jamal MH, et al. 2020.. Characteristics, risk factors and outcomes among the first consecutive 1,096 patients diagnosed with COVID-19 in Kuwait. . Lancet EClinicalMedicine 24::100448
     [Google Scholar]
  33. 33. 
    Bhandari S, Singh A, Sharma R. 2020.. Characteristics, treatment outcomes and role of hydroxychloroquine among 522 COVID-19 hospitalized patients in Jaipur City: an epidemio-clinical study. . J. Assoc. Phys. India 68:(6):13–19
     [Google Scholar]
  34. 34. 
    Li B, Yang J, Zhao F, et al. 2020.. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. . Clin. Res. Cardiol. 109:(5):531–38
     [Google Scholar]
  35. 35. 
    Yang J, Zheng Y, Gou X, et al. 2020.. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. . Int. J. Infect. Dis. 94::91–95
     [Google Scholar]
  36. 36. 
    Emami A, Javanmardi F, Pirbonyeh N, Akbari A. 2020.. Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. . Arch. Acad. Emerg. Med. 8:(1):e35
     [Google Scholar]
  37. 37. 
    Hu Y, Sun J, Dai Z, et al. 2020.. Prevalence and severity of corona virus disease 2019 (COVID-19): a systematic review and meta-analysis. . J. Clin. Virol. 127::104371
     [Google Scholar]
  38. 38. 
    Wang L, Gao P, Zhang M, Huang Z, Zhang D, et al. 2017.. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. . JAMA 317::2515–23
     [Google Scholar]
  39. 39. 
    Mithal A, Jevalikar G, Sharma R, et al. 2020.. High prevalence of diabetes and other comorbidities in hospitalized patients with COVID-19 in Delhi, India, and their association with outcomes. . Diabetes Metab. Syndr. 15::169–75
     [Google Scholar]
  40. 40. 
    Anjana RM, Deepa M, Pradeepa R, et al. 2017.. Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR-INDIAB population-based cross-sectional study. . Lancet Diabetes Endocrinol. 5:(8):585e96
     [Google Scholar]
  41. 41. 
    Richardson S, Hirsch JS, Narasimhan M, et al. 2020.. Northwell COVID-19 Research Consortium. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. . JAMA 323::2052–59
     [Google Scholar]
  42. 42. 
    Hartmann-Boyce J, Morris E, Goyder C, et al. 2020.. Diabetes and risks from COVID-19. . The Centre for Evidence-Based Medicine. Accessed Apr. 16, 2021. https://www.cebm.net/covid-19/diabetes-and-risks-from-covid-19/
    [Google Scholar]
  43. 43. 
    Chen YM, Gong X, Wang L, Guo J. 2020.. Effects of hypertension, diabetes and coronary heart disease on COVID-19 diseases severity: a systematic review and meta-analysis. . medRxiv https://doi.org/10.1101/2020.03.25.20043133
    [Crossref]
  44. 44. 
    Roncon L, Zuin M, Rigatelli G, Zuliani G. 2020.. Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. . J. Clin. Virol. 127::104354
     [Google Scholar]
  45. 45. 
    Wang B, Li R, Lu Z, Huang Y. 2020.. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. . Aging 12::6049–57
     [Google Scholar]
  46. 46. 
    Kumar A, Arora A, Sharma O, et al. 2020.. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. . Diabetes Metab. Syndr. 14:(4):535–45
     [Google Scholar]
  47. 47. 
    Huang I, Lim MA, Pranata R, et al. 2020.. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia—a systematic review, meta-analysis, and meta-regression. . Diabetes Metab. Syndr. 14:(4):395–403
     [Google Scholar]
  48. 48. 
    Bode B, Garrett V, Messler J, et al. 2020.. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. . J. Diabetes Sci. Technol. 14:(4):813–21
     [Google Scholar]
  49. 49. 
    Guo W, Li M, Dong Y, et al. 2020.. Diabetes is a risk factor for the progression and prognosis of COVID-19. . Diabetes Metab. Res. Rev. 36:(7):e3319
     [Google Scholar]
  50. 50. 
    Deleted in proof
  51. 51. 
    Zhu L, She AG, Cheng X, et al. 2020.. Association of blood glucose control and outcomes in patients with COVID-19 and preexisting type 2 diabetes. . Cell Metab. 31::1068–77
     [Google Scholar]
  52. 52. 
    Vangoitsenhoven R, Martens PJ, Nes FV, et al. 2020.. No evidence of increased hospitalization rate for COVID-19 in community-dwelling patients with type 1 diabetes. . Diabetes Care 43::e118–19
     [Google Scholar]
  53. 53. 
    Vamvini M, Lioutas VA, Middelbeek RJW. 2020.. Characteristics and diabetes control in adults with type 1 diabetes admitted with COVID-19 infection. . Diabetes Care 43::e120–22
     [Google Scholar]
  54. 54. 
    Wargny M, Gourdy P, Ludwing L, et al. 2020.. Type 1 diabetes in people hospitalized for COVID-19: new insights from the CORONADO study. . Diabetes Care 43::e174–77
     [Google Scholar]
  55. 55. 
    Wang S, Ma P, Zhang S, et al. 2020.. Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study. . Diabetologia 63::2102–11
     [Google Scholar]
  56. 56. 
    Li H, Tian S, Chen T, et al. 2020.. Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19. . Diabetes Obes. Metab. 22:(10):1897–906
     [Google Scholar]
  57. 57. 
    Fadini GP, Morieri ML, Boscari F, et al. 2020.. Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration. . Diabetes Res. Clin. Pract. 168::108374
     [Google Scholar]
  58. 58. 
    Zhang Y, Li H, Zhang J, et al. 2020.. The clinical characteristics and outcomes of patients with diabetes and secondary hyperglycaemia with coronavirus disease 2019: a single-centre, retrospective, observational study in Wuhan. . Diabetes Obes. Metab. 22:(8):1443–54
     [Google Scholar]
  59. 59. 
    Sardu C, D'Onofrio N, Balestrieri ML, et al. 2020.. Hyperglycaemia on admission to hospital and COVID-19. . Diabetologia 63:(11):2486–87
     [Google Scholar]
  60. 60. 
    Coppelli A, Giannarelli R, Aragona M, et al. 2020.. Hyperglycemia at hospital admission is associated with severity of the prognosis in patients hospitalized for COVID-19: the Pisa COVID-19 study. . Diabetes Care 43:(10):2345–48
     [Google Scholar]
  61. 61. 
    Yang JK, Jin JM, Liu S, et al. 2020.. New onset COVID-19–related diabetes: an indicator of mortality. . medRxiv https://doi.org/10.1101/2020.04.08.20058040
    [Crossref]
  62. 62. 
    Capes SE, Hunt D, Malmberg K, Gerstein HC. 2000.. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. . Lancet 355:(9206):773–78
     [Google Scholar]
  63. 63. 
    Rubino F, Amiel SA, Zimmet P, et al. 2020.. New-onset diabetes in Covid-19. . N. Engl. J. Med. 383:(8):789–90
     [Google Scholar]
  64. 64. 
    Singh AK, Singh R. 2020.. Is metformin ahead in the race as a repurposed host-directed therapy for patients with diabetes and COVID-19?. Diabetes Res. Clin. Pract. 165::108268
     [Google Scholar]
  65. 65. 
    Chen Y, Yang D, Cheng B, et al. 2020.. Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication. . Diabetes Care 43:(7):1399–407
     [Google Scholar]
  66. 66. 
    Kim MK, Jeon JH, Kim SW, et al. 2020.. The clinical characteristics and outcomes of patients with moderate-to-severe coronavirus disease 2019 infection and diabetes in Daegu, South Korea. . Diabetes Metab. J. 44:(4):602–13
     [Google Scholar]
  67. 67. 
    Philipose Z, Smati N, Wong CSJ, et al. 2020.. Obesity, old age, and frailty are the true risk factors for COVID-19 mortality and not chronic disease or ethnicity. . medRxiv https://doi.org/10.1101/2020.08.12.20156257
    [Crossref]
  68. 68. 
    Izzi-Engbeaya C, Distaso W, Amin A, et al. 2020.. Severe COVID-19 and diabetes—a retrospective cohort study from three London teaching hospitals. . medRxiv https://doi.org/10.1101/2020.08.07.20160275
    [Crossref] [Google Scholar]
  69. 69. 
    Lalau JD, Al-Salameh A, Hadjadj S, et al. 2020.. Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalized for COVID-19. . Diabetes Metab. 47:(5):101216
     [Google Scholar]
  70. 70. 
    Gao Y, Liu T, Zhong W, et al. 2020.. Risk of metformin in type 2 diabetes patients with COVID-19: a preliminary retrospective report. . Clin. Transl. Sci. 13:(6):1055–59
     [Google Scholar]
  71. 71. 
    Luo P, Qiu L, Liu Y, et al. 2020.. Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis. . Am. J. Trop. Med. Hyg. 103:(1):69–72
     [Google Scholar]
  72. 72. 
    Abu-Jamous B, Anisimovich A, Baxter J, et al. 2020.. Associations of comorbidities and medications with COVID-19 outcome: a retrospective analysis of real-world evidence data. . medRxiv https://doi.org/10.1101/2020.08.20.20174169
    [Crossref]
  73. 73. 
    Crouse AB, Grimes T, Li P, et al. 2020.. Metformin use is associated with reduced mortality in a diverse population with COVID-19 and diabetes. . medRxiv https://doi.org/10.1101/2020.07.29.20164020
    [Crossref]
  74. 74. 
    Bramante CT, Ingraham NE, Murray TA, et al. 2021.. Metformin and risk of mortality in patients hospitalized with Covid-19: a retrospective cohort analysis. . Lancet Healthy Longev. 2::e34–e41
     [Google Scholar]
  75. 75. 
    Jiang N, Chen Z, Yin X, et al. 2021.. Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: a retrospective cohort study. . Diabetes Res. Clin. Pract. 173::108619
     [Google Scholar]
  76. 76. 
    Cheng X, Liu YM, Li H, et al. 2020.. Metformin use is associated with increased incidence of acidosis but not mortality in individuals with COVID-19 and pre-existing type 2 diabetes. . Cell Metab. 32:(4):537–47
     [Google Scholar]
  77. 77. 
    Khunti K, Knighton P, Zaccardi F, et al. 2021.. Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England. . Lancet Diabetes Endocrinol. 9:(5):293–303
     [Google Scholar]
  78. 78. 
    Scheen AJ. 2020.. Metformin and COVID-19: from cellular mechanisms to reduced mortality. . Diabetes Metab. 46::423–26
     [Google Scholar]
  79. 79. 
    Kow CS, Hasan SS. 2020.. Mortality risk with preadmission metformin use in patients with COVID-19 and diabetes: a meta-analysis. . J. Med. Virol. 93:(2):695–97
     [Google Scholar]
  80. 80. 
    Hariyanto TI, Kurniawan A. 2020.. Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection. . Obes. Med. 19::100290
     [Google Scholar]
  81. 81. 
    Lukito AA, Pranata R, Henrina J, et al. 2020.. The effect of metformin consumption on mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis. . Diabetes Metab. Syndr. 14:(6):2177–83
     [Google Scholar]
  82. 82. 
    Vankadari N, Wilce JA. 2020.. Emerging Wuhan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. . Emerg. Microb. Infect. 9:(1):601e4
     [Google Scholar]
  83. 83. 
    Li Y, Zhang Z, Yang L, et al. 2020.. The MERS-CoV receptor DPP4 as a candidate binding target of the SARS-CoV-2 spike. . iScience 23:(6):101160
     [Google Scholar]
  84. 84. 
    Singh AK, Singh R. 2020.. DPP-4 inhibitors in type 2 diabetes and COVID-19: from a potential repurposed agent to a useful treatment option. . J. Diabetol. 11::131–36
     [Google Scholar]
  85. 85. 
    Drucker DJ. 2020.. Coronavirus infections and type 2 diabetes—shared pathways with therapeutic implications. . Endocr. Rev. 41:(3):bnna011
     [Google Scholar]
  86. 86. 
    Wargny M, Potier L, Gourdy P, et al. 2021.. Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study. . Diabetologia 64:(4):778–94
     [Google Scholar]
  87. 87. 
    Fadini GP, Morieri ML, Longato E, et al. 2020.. Exposure to DPP-4 inhibitors and COVID-19 among people with type 2 diabetes. A case-control study. . Diabetes Obes. Metab. 22:(10):1946–50
     [Google Scholar]
  88. 88. 
    Strollo R, Maddaloni E, Dauriz M, et al. 2021.. Use of DPP4 inhibitors in Italy does not correlate with diabetes prevalence among COVID-19 deaths. . Diabetes Res. Clin. Pract. 171::108444
     [Google Scholar]
  89. 89. 
    Dalan R, Ang LW, Tan WY, et al. 2021.. The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study. . Eur. Heart J. Cardiovasc. Pharmacother. 7:(3):e48–e51
     [Google Scholar]
  90. 90. 
    Montastruc F, Romano C, Montastruc J-Louis, et al. 2020.. Pharmacological characteristics of patients infected with SARS-Cov-2 admitted to intensive care unit in South of France. . Therapies 75:(4):381–84
     [Google Scholar]
  91. 91. 
    Rhee SY, Lee J, Nam H, et al. 2020.. Effects of a DPP-4 inhibitor and RAS blockade on clinical outcomes of patients with diabetes and COVID-19. . medRxiv https://doi.org/10.1101/2020.05.20.20108555
    [Crossref]
  92. 92. 
    Mirani M, Favacchio G, Carrone F, et al. 2020.. Impact of comorbidities and glycemia at admission and dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes with COVID-19: a case series from an academic hospital in Lombardy, Italy. . Diabetes Care 43::3042–49
     [Google Scholar]
  93. 93. 
    Solerte SB, D'Addio F, Trevisan R, et al. 2020.. Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with type 2 diabetes and COVID-19: a multicenter, case-control, retrospective, observational study. . Diabetes Care 43::2999–3006
     [Google Scholar]
  94. 94. 
    Bonora BM, Avogaro A, Fadini GP. 2021.. Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis. . J. Endocrinol. Investig. 44:(7):137986
     [Google Scholar]
  95. 95. 
    Rakhmat II, Kusmala YY, Handayani DR, et al. 2021.. Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19)—a systematic review, meta-analysis, and meta-regression. . Diabetes Metab. Syndr. 15::777–82
     [Google Scholar]
  96. 96. 
    Hariyanto TI, Kurniawan A. 2021.. Dipeptidyl peptidase 4 (DPP4) inhibitor and outcome from coronavirus disease 2019 (COVID-19) in diabetic patients: a systematic review, meta-analysis, and meta-regression. . J. Diabetes Metab. Disord. 20:(1):1–8
     [Google Scholar]
  97. 97. 
    Zelniker TA, Wiviott SD, Raz I, et al. 2019.. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. . Lancet. 393:(10166):31–39
     [Google Scholar]
  98. 98. 
    AstraZeneca. 2021.. Update on the DARE-19 Phase III trial for Farxiga in COVID-19. Press release, Apr.12 , AstraZeneca, Cambridge, UK:. https://www.astrazeneca.com/media-centre/press-releases/2021/update-on-farxiga-covid-19-dare-19-phase-iii-trial.html
    [Google Scholar]
  99. 99. 
    Nauck MA, Meier JJ. 2020.. Reduced COVID-19 mortality with sitagliptin treatment? Weighing the dissemination of potentially lifesaving findings against the assurance of high scientific standards. . Diabetes Care 43::2906–9
     [Google Scholar]
/content/journals/10.1146/annurev-med-042220-011857
Loading
COVID-19 and Diabetes
Annual Review of Medicine 73, 129 (2022); https://doi.org/10.1146/annurev-med-042220-011857
/content/journals/10.1146/annurev-med-042220-011857
/content/journals/10.1146/annurev-med-042220-011857
Loading

Data & Media loading...

  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error